Recombinant SARS-CoV-2 Spike S1 抗体 (RBD)
Quick Overview for Recombinant SARS-CoV-2 Spike S1 抗体 (RBD) (ABIN6953042)
抗原
See all SARS-CoV-2 Spike S1 抗体抗体类型
适用
宿主
克隆类型
标记
应用范围
克隆位点
-
-
抗原表位
- RBD
-
原理
- Recombinant monoclonal antibody to COVID-19 & SARS-CoV S glycoprotein.
-
特异性
-
The antibody CR3022 binds the amino acids 318-510 in the S1 domain of the SARS-CoV Spike protein as well as SARS-CoV-2 (COVID-19) Spike protein. The antibody also binds to P462L-substituted S318-510 fragments of the SARS spike protein. The binding epitope is only accessible in the "open" conformation of the spike protein (Joyce et al. 2020).
While most S-protein RBD binding antibodies compete for antigen binding with ACE2, the CR3022 epitope does not overlap with the ACE2-binding site. It does thus not hinder binding of neutralizing antibodies. While CR3022 on its own exhibits only a weak neutralizing effect, it has been shown to synergize with other S-protein RBD binding antibodies to neutralize SARS-CoV. This effect still has to be confirmed in context with SARS-CoV-2 (Yuan et al. 2020).
-
交叉反应 （详细）
- The anti-SARS-CoV-2 antibody CR3022 was originally discovered in a SARS patient, but it was shown to be a potent binder of SARS-CoV-2 spike protein (S1).
-
产品特性
-
Original Species of Ab: Human
Original Format of Ab: IgG1
-
纯化方法
- Affinity Purified using a recombinant lectin column
-
免疫原
- The original monoclonal antibody was generated through an scFv library derived from a peripheral blood lymphocytes of a patient exposed to the SARS-CoV.
-
亚型
- IgM kappa
-
-
anti-SARS-CoV-2 Spike S1 (RBD) antibody
适用: SARS Coronavirus-2 (SARS-CoV-2), SARS Coronavirus (SARS-CoV), SARS CoV-2 Alpha, SARS CoV-2 Beta, SARS CoV-2 Epsilon, SARS CoV-2 Gamma, SARS CoV-2 Eta, SARS CoV-2 Kappa, SARS CoV-2 Delta, SARS CoV-2 Omicron ELISA, IF, Crys, SPR 宿主: Human Monoclonal CR3022 unconjugated Recombinant Antibody
anti-SARS-CoV-2 Spike S1 (RBD) antibody适用: SARS Coronavirus-2 (SARS-CoV-2), SARS Coronavirus (SARS-CoV), SARS CoV-2 Alpha, SARS CoV-2 Beta, SARS CoV-2 Epsilon, SARS CoV-2 Gamma, SARS CoV-2 Eta, SARS CoV-2 Kappa ELISA, IF, Crys, SPR 宿主: 兔 Chimeric CR3022 unconjugated Recombinant Antibody
anti-SARS-CoV-2 Spike S1 (RBD) antibody适用: SARS Coronavirus-2 (SARS-CoV-2) ELISA, GICA, Neut 宿主: Human Monoclonal A1 unconjugated single-domain Antibody (sdAb) Recombinant Antibody
anti-SARS-CoV-2 Spike S1 antibody适用: SARS Coronavirus-2 (SARS-CoV-2), SARS CoV-2 Alpha, SARS CoV-2 Beta, SARS CoV-2 Epsilon, SARS CoV-2 Gamma ELISA, Neut 宿主: Human Chimeric AM122 unconjugated
anti-SARS-CoV-2 Spike S1 antibody适用: SARS Coronavirus-2 (SARS-CoV-2) ELISA, GICA 宿主: Human Chimeric H6 unconjugated Recombinant Antibody
anti-SARS-CoV-2 Spike S1 (RBD) antibody适用: SARS Coronavirus-2 (SARS-CoV-2) ELISA 宿主: 兔 Polyclonal unconjugated
anti-SARS-CoV-2 Spike S1 antibody (Biotin)适用: SARS Coronavirus-2 (SARS-CoV-2) ELISA 宿主: Human Monoclonal H6 Biotin scFv fragment Recombinant Antibody
anti-SARS-CoV-2 Spike S1 antibody (HRP)适用: SARS Coronavirus-2 (SARS-CoV-2) ELISA 宿主: Human Monoclonal H6 HRP scFv fragment Recombinant Antibody
anti-SARS-CoV-2 Spike S1 antibody适用: SARS Coronavirus-2 (SARS-CoV-2), SARS CoV-2 Alpha ELISA, IHC 宿主: 兔 Monoclonal SP185 unconjugated
anti-SARS-CoV-2 Spike S1 (RBD) antibody适用: SARS Coronavirus-2 (SARS-CoV-2), SARS Coronavirus (SARS-CoV) ELISA, IF, Crys, SPR 宿主: Human Monoclonal CR3022 unconjugated Recombinant Antibody
-
-
应用备注
- This antibody binds to both SARS-CoV and SARS-CoV-2 with high affinity (PMID: 16796401 & 32065055). The initial characterization of the binding of this antibody was performed by ELISA and indicates potential for the development of diagnostic assays, as both virus-capture assays, or as controls in serological assays measuring immune-responses to virus exposure. Human IgG1, IgG3, IgM and IgA isotypes are available to mimic antibody responses seen in COVID19 < a href="https://www.medrxiv.org/content/10.1101/2020.03.17.20037713v1" target="_blank">(Amanat et al. 2020). Human IgG2 and IgG4 subtypes, which are also seen in a small subset of COVID-19 patients, are also available to investigate their role in the response to SARS-CoV-2. The original human IgG1 version of the antibody works synergistically in combination with another non-ompeting SARS antibody CR3014 and is a potential candidate for passive immune prophylaxis of SARS-CoV infection (Meulen et al., 2006). The original antibody (human IgG1) was also reported to bind the 2019-nCoV RBD (KD of 6.3 nM). This antibody has been attributed a potential to be developed as a therapeutic agent, alone or in combination with other neutralizing antibodies for treatment of 2019-nCoV infections (Tian et al., 2020). Bates et al. 2021 (PMID: 32766589) used CR3022 in a immunofluorescence assay.
-
说明
-
This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
浓度
- 1 mg/mL
-
缓冲液
- PBS with 0.02 % Proclin 300.
-
储存液
- ProClin
-
注意事项
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
储存条件
- 4 °C,-20 °C
-
储存方法
- Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
-
-
- SARS-CoV-2 Spike S1
-
物质类
- Viral Protein
-
背景
- Spike protein, COVID19, COVID 19, S protein, SARS-CoV S protein, S glycoprotein, E2, Peplomer protein, Spike protein S1, SARS Coronavirus, SARS-CoV-2, SARS CoV 2, 2019-nCoV, Ab1680.10, Ab1680.15, Ab1680.16
-
UniProt
- P59594
抗原
-
